<DOC>
	<DOCNO>NCT01409135</DOCNO>
	<brief_summary>A study examine safety AGS-22M6E ASG-22CE administer monotherapy therapy subject malignant solid tumor express Nectin-4 .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics AGS-22M6E Subjects With Malignant Solid Tumors That Express Nectin-4</brief_title>
	<detailed_description>AGS-22M6E ASG-22CE fully human monoclonal antibody conjugate cytotoxic agent monomethyl auristatin E ( MMAE ) target Nectin-4 ( Agensys code name AGS-22 ) . The main difference AGS-22M6E ASG-22CE change cell line antibody production . AGS-22M6E ASG-22CE administer mg/kg dos base subject weight baseline dos change unless subject weight change ≥ 10 % baseline weight investigational product Dosage Assessment criterion meet . Subjects prescreened Nectin-4 expression prior undergo screen procedure main study . Subjects tumor positive Nectin-4 expression may screen eligibility main study . The dose escalation period estimate take 12 18 month depend whether 3 6 subject enrol give dose cohort , availability consent subject . Subjects treat dose escalation phase study maximum tolerate dose ( MTD ) recommend dose expansion ( RDE ) determine data review team ( DRT ) . After RDE determine , subject enrol 1 3 expansion cohort . There 3 expansion cohort , target specific cancer ( i.e. , Breast , Bladder Lung plus solid tumor cancer ) . The DRT may recommend stop study , adjust dose amend trial time . The clinical bridging ASG-22CE involve treat subject ASG-22CE , irrespective cancer type , next low dose level previously determine safe AGS-22M6E . After initial subject treat bridge dose ASG-22CE complete safety assessment , future subject treat ASG-22CE throughout remainder study . A disease assessment perform investigator Week 8 ( ± 14 day ) . Subjects without evidence disease progression may continue receive treatment disease progression intolerability .</detailed_description>
	<criteria>( For Dose Escalation Dose Expansion ) Subjects must tumor positive Nectin4 expression ( measured central laboratory use primary metastatic tumor tissue Histologically confirm malignant solid tumor ( exclude sarcoma ) fail FDA approve therapy indicate type metastatic cancer line therapy candidate receive treatment Measurable disease accord RECIST criterion ( version 1.1 ) ( Eisenhauer , et . al . ) define tumor lesion accurately measure least one dimension ( long diameter plane measurement record ) minimum size : 10mm CT scan ( CT scan slice thickness great 5mm 10 mm caliper measurement clinical exam ( lesion accurately measure caliper record nonmeasurable 20 mm chest Xray ≥ 15 mm short axis lymph node assess CT scan ( CT scan slice thickness recommend great 5 mm ) Note : bone lesion , ascites , pleural effusion consider measurable lesion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Negative pregnancy test ( woman childbearing potential ) Hematologic function , follow : . Absolute neutrophil count ( ANC ) ≥ 1.0 x109 /L b. Platelet count ≥ 100 x 109/L c. Hemoglobin ≥ 8.5 g/dL Renal function , follow : serum creatinine ≤ 2.0 mg/dL , measure 24 hour creatinine clearance ≥ 45 mL/min Total bilirubin ≤1.5 x upper limit normal ( ULN ) Serum albumin &gt; 2.5 g/dL Aspartate aminotransferase ( AST ) ≤ 1.5 x ULN Alanine aminotransferase ( ALT ) ≤ 1.5 x ULN Gamma GT ≤1.5 ULN International normalize ratio ( INR ) &lt; 1.5 ( ≤ 3 warfarin medication therapeutic anticoagulation ) Women men childbearing potential must advise agree practice effective method contraception course study Inclusion Criteria Dose Expansion Only : In addition inclusion criterion list , follow criterion also required expansion cohort : Expansion Cohort 1 : Breast Cancer Subjects Histologically cytologically diagnose metastatic breast cancer Expansion Cohort 2 : Bladder Cancer Histologically cytologically confirm bladder cancer visceral metastasis Expansion Cohort 3 : Lung plus solid tumor cancer Histologically cytologically confirm metastatic nonsmall cell lung cancer ( NSCLC ) solid tumor cancer Preexisting neuropathy Grade ≥ 3 motor neuropathy Grade ≥ 2 Uncontrolled brain epidural spinal metastasis Use investigational drug within 14 day 5 halflives prior first dose study drug Any anticancer therapy include : small molecule , immunotherapy , chemotherapy , monoclonal antibody therapy , radiotherapy agent treat cancer within 28 day prior first dose study drug Active angina Class III IV Congestive Heart Failure ( New York Heart Association CHF Functional Classification System ) clinically significant cardiac disease within 12 month first dose study drug , include myocardial infarction , unstable angina , grade 2 great peripheral vascular disease , congestive heart failure , uncontrolled hypertension , arrhythmias control medication Known HIV AIDS Decompensated liver disease evidence clinically significant ascites refractory diuretic therapy , hepatic encephalopathy , coagulopathy History thromboembolic event bleed disorder ≤ 3 month ( e.g. , deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) ) prior first dose study drug Major surgery within 28 day prior first dose study drug Active infection require treatment ≤7 day prior first dose study drug Antiandrogen therapy initiate within 28 day enrollment ( prostate cancer patient ) Positive Hepatitis B surface antigen test Positive Hepatitis C antibody test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Nectin 4 protein , human</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pharmacokinetics AGS-22M6E</keyword>
	<keyword>Pharmacokinetics ASG-22CE</keyword>
	<keyword>Safety</keyword>
	<keyword>Clinical Trial , Phase 1</keyword>
	<keyword>ASG-22ME</keyword>
	<keyword>AGS-22M6E</keyword>
	<keyword>ASG-22CE</keyword>
	<keyword>ASG-22C3</keyword>
</DOC>